Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
95.49
+0.79 (0.83%)
Dec 23, 2024, 4:00 PM EST
Novartis AG Revenue
Novartis AG had revenue of $13.17B in the quarter ending September 30, 2024, with 8.93% growth. This brings the company's revenue in the last twelve months to $49.94B, up 8.92% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
49.94B
Revenue Growth
+8.92%
P/S Ratio
n/a
Revenue / Employee
656.61K
Employees
76,057
Market Cap
194.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.66B |
| Ryman Healthcare Limited | 458.44M |
| Verano Holdings Corp. | 897.57M |
| Vireo Growth Inc. | 98.53M |
| Medexus Pharmaceuticals Inc. | 104.76M |
Novartis AG News
- 5 days ago - Novartis to close MorphoSys sites in Boston, Munich: report - Seeking Alpha
- 5 days ago - Some 330 jobs hit as Novartis closes Morphosys, WiWo reports - Reuters
- 6 days ago - BioAge, Novartis team up to discover age-related disease targets - Seeking Alpha
- 7 days ago - Novartis participates in Healthway Cancer Care Hospital ‘Celebrating Strength’ event championing breast cancer survivorship - BusinessMirror
- 11 days ago - Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Benzinga
- 11 days ago - Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report - Benzinga
- 11 days ago - Novartis: Time To Increase - Seeking Alpha
- 14 days ago - Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer - GlobeNewsWire